Financial Performance - The company reported total revenue of RMB 1,399,808,311.93 for Q1 2024, a decrease of 37.76% compared to RMB 2,249,034,497.62 in the same period last year[10]. - Net profit attributable to shareholders was RMB 281,970,252.06, down 55.27% from RMB 630,346,004.43 year-on-year[10]. - The net profit after deducting non-recurring items was RMB 253,974,228.11, reflecting a 58.88% decline compared to RMB 617,637,901.61 in the previous year[10]. - Basic and diluted earnings per share were both RMB 0.76, down 55.81% from RMB 1.72 in the same period last year[10]. - Total revenue for Q1 2024 was approximately ¥1.40 billion, a decrease of 37.76% compared to ¥2.25 billion in Q1 2023, primarily due to the impact of large orders in the same period last year[18]. - Operating profit decreased to RMB 294.69 million, a decline of 58.5% compared to RMB 709.95 million in the prior period[38]. - Net profit for the reporting period was RMB 279.53 million, down 55.5% from RMB 627.89 million in the previous period[40]. - Total revenue for the reporting period was RMB 1.40 billion, down 37.8% from RMB 2.25 billion in the previous period[38]. - The company reported a net loss attributable to the parent company of RMB 281,971,000 in Q1 2024, compared to a profit of RMB 630,346,000 in Q1 2023[47]. Revenue Breakdown - Revenue from small molecule business reached RMB 1,223,000,000, with a year-on-year growth of 26.58% after excluding last year's large order impact[13]. - Revenue from emerging businesses was RMB 176,000,000, down 29.30% year-on-year due to the ongoing impact of the domestic investment environment[13]. - Cash received from sales of goods and services was approximately ¥1.74 billion, down 36.76% from ¥2.76 billion in the previous year, influenced by large order repayments from last year[18]. Costs and Expenses - Total costs for Q1 2024 were approximately ¥1.14 billion, down 27.27% from ¥1.57 billion in Q1 2023, mainly due to the decline in revenue[18]. - Sales expenses increased by 31.95% to approximately ¥44.62 million, reflecting continued investment in market expansion and sales activities[18]. - The company reported a significant increase in tax and additional charges, which rose by 374.77% to approximately ¥41 million, attributed to export tax rebates[18]. - Research and development expenses for the period were RMB 169.44 million, an increase from RMB 162.10 million in the previous period[38]. - Research and development expenses for Q1 2024 were RMB 169,442,000, slightly higher than RMB 162,097,000 in Q1 2023[47]. Assets and Liabilities - Total assets at the end of the reporting period were RMB 19,841,423,232.54, a slight increase of 0.38% from RMB 19,767,158,652.70 at the end of the previous year[10]. - Total current assets decreased to RMB 12.11 billion from RMB 12.35 billion, primarily due to a reduction in trading financial assets[31]. - The company reported a total liability of RMB 2.23 billion, slightly down from RMB 2.26 billion at the beginning of the period[35]. - The company’s total equity as of March 31, 2024, was RMB 17,606,958,000, an increase from RMB 17,509,979,000 at the end of the previous year[55]. Cash Flow and Investments - Net cash flow from operating activities for the reporting period was RMB 490,666,474.36, significantly lower than RMB 1,303,525,263.66 in the previous period[44]. - Cash and cash equivalents at the end of Q1 2024 totaled RMB 4,774,669,819.21, down from RMB 5,379,198,112.41 at the end of the previous year[45]. - The cash flow from investing activities showed a net outflow of RMB 284,603,126.59, compared to a net outflow of RMB 327,218,213.85 in the previous period[44]. - The company experienced a foreign exchange gain of RMB 15,685,123.62 during the reporting period, contrasting with a loss of RMB 15,286,791.15 in the previous period[45]. - The company experienced a net cash outflow from investing activities of RMB 284,603 thousand in Q1 2024, compared to RMB 327,218 thousand in Q1 2023[59]. Share Repurchase and Capital Management - The company repurchased shares, resulting in cash payments of approximately ¥218.69 million, marking a new strategy in capital management[18]. - The company plans to repurchase shares with a total fund amount not less than RMB 600 million and not exceeding RMB 1.2 billion, with a repurchase price not exceeding RMB 157 per share[29]. - The financing activities resulted in a net cash outflow of RMB 218,690 thousand in Q1 2024, with share repurchase payments amounting to RMB 213,367 thousand[59]. Project Development - The company confirmed 30 small molecule commercialization projects and 148 clinical stage projects, including 41 in Phase III[13].
凯莱英(06821) - 2024 Q1 - 季度业绩